142 related articles for article (PubMed ID: 8453625)
1. Tamoxifen modulation of cisplatin sensitivity in human malignant melanoma cells.
McClay EF; Albright KD; Jones JA; Christen RD; Howell SB
Cancer Res; 1993 Apr; 53(7):1571-6. PubMed ID: 8453625
[TBL] [Abstract][Full Text] [Related]
2. Modulation of cisplatin resistance in human malignant melanoma cells.
McClay EF; Albright KD; Jones JA; Eastman A; Christen R; Howell SB
Cancer Res; 1992 Dec; 52(24):6790-6. PubMed ID: 1458467
[TBL] [Abstract][Full Text] [Related]
3. Determinants of tamoxifen sensitivity control the nature of the synergistic interaction between tamoxifen and cisplatin.
McClay EF; Jones JA; Winski PJ; Albright KD; Christen RD; Howell SB
Cancer Res; 1996 Sep; 56(17):3993-7. PubMed ID: 8752169
[TBL] [Abstract][Full Text] [Related]
4. Synergy between tamoxifen and cisplatin in human melanoma cells is dependent on the presence of antiestrogen-binding sites.
Jones JA; Albright KD; Christen RD; Howell SB; McClay EF
Cancer Res; 1997 Jul; 57(13):2657-60. PubMed ID: 9205073
[TBL] [Abstract][Full Text] [Related]
5. Tamoxifen induces p21WAF1 and p27KIP1 expression in estrogen receptor-negative lung cancer cells.
Lee TH; Chuang LY; Hung WC
Oncogene; 1999 Jul; 18(29):4269-74. PubMed ID: 10435640
[TBL] [Abstract][Full Text] [Related]
6. The role of tamoxifen in combination with cisplatin on oral squamous cell carcinoma cell lines.
Kim MJ; Lee JH; Kim YK; Myoung H; Yun PY
Cancer Lett; 2007 Jan; 245(1-2):284-92. PubMed ID: 16513256
[TBL] [Abstract][Full Text] [Related]
7. Activity of platinum drugs against melanoma cell lines: is it modulated in vitro in the presence of tamoxifen?
Mohammed MQ; Photiou A; Shah P; Retsas S
Anticancer Res; 1995; 15(4):1319-26. PubMed ID: 7654015
[TBL] [Abstract][Full Text] [Related]
8. Tamoxifen modulation of cisplatin cytotoxicity in human malignancies.
McClay EF; Albright KD; Jones JA; Christen RD; Howell SB
Int J Cancer; 1993 Dec; 55(6):1018-22. PubMed ID: 8253520
[TBL] [Abstract][Full Text] [Related]
9. Increase of cisplatin sensitivity by c-myc antisense oligodeoxynucleotides in a human metastatic melanoma inherently resistant to cisplatin.
Leonetti C; Biroccio A; Candiloro A; Citro G; Fornari C; Mottolese M; Del Bufalo D; Zupi G
Clin Cancer Res; 1999 Sep; 5(9):2588-95. PubMed ID: 10499637
[TBL] [Abstract][Full Text] [Related]
10. Induction of p21WAF1 expression via Sp1-binding sites by tamoxifen in estrogen receptor-negative lung cancer cells.
Lee TH; Chuang LY; Hung WC
Oncogene; 2000 Aug; 19(33):3766-73. PubMed ID: 10949931
[TBL] [Abstract][Full Text] [Related]
11. Tamoxifen in the treatment of metastatic malignant melanoma: still a controversy? (Review).
Toma S; Ugolini D; Palumbo R
Int J Oncol; 1999 Aug; 15(2):321-37. PubMed ID: 10402244
[TBL] [Abstract][Full Text] [Related]
12. Tamoxifen delays the development of resistance to cisplatin in human melanoma and ovarian cancer cell lines.
McClay EF; Albright KD; Jones JA; Christen RD; Howell SB
Br J Cancer; 1994 Sep; 70(3):449-52. PubMed ID: 8080729
[TBL] [Abstract][Full Text] [Related]
13. Tamoxifen modulation of cisplatin resistance in patients with metastatic melanoma. A biologically important observation.
Mc Clay EF; Mc Clay ME; Albright KD; Jones JA; Christen RD; Alcaraz J; Howell SB
Cancer; 1993 Sep; 72(6):1914-8. PubMed ID: 8364868
[TBL] [Abstract][Full Text] [Related]
14. Activation of caspase-3 and c-Jun NH2-terminal kinase-1 signaling pathways in tamoxifen-induced apoptosis of human breast cancer cells.
Mandlekar S; Yu R; Tan TH; Kong AN
Cancer Res; 2000 Nov; 60(21):5995-6000. PubMed ID: 11085519
[TBL] [Abstract][Full Text] [Related]
15. Increased activator protein-1 DNA binding and c-Jun NH2-terminal kinase activity in human breast tumors with acquired tamoxifen resistance.
Johnston SR; Lu B; Scott GK; Kushner PJ; Smith IE; Dowsett M; Benz CC
Clin Cancer Res; 1999 Feb; 5(2):251-6. PubMed ID: 10037172
[TBL] [Abstract][Full Text] [Related]
16. Molecular changes associated with the agonist activity of hydroxy-tamoxifen and the hyper-response to estradiol in hydroxy-tamoxifen-resistant breast cancer cell lines.
Vendrell JA; Bieche I; Desmetz C; Badia E; Tozlu S; Nguyen C; Nicolas JC; Lidereau R; Cohen PA
Endocr Relat Cancer; 2005 Mar; 12(1):75-92. PubMed ID: 15788640
[TBL] [Abstract][Full Text] [Related]
17. delta 12-Prostaglandin-J2 is cytotoxic in human malignancies and synergizes with both cisplatin and radiation.
McClay EF; Winski PJ; Jones JA; Jennerette J; Gattoni-Celli S
Cancer Res; 1996 Sep; 56(17):3866-9. PubMed ID: 8752147
[TBL] [Abstract][Full Text] [Related]
18. [Status of estrogen receptor affects the drug sensitivity of drug-resistant MCF-7/Adr human breast cancer cells to droloxifene and Adriamycin].
Gao HD; Sun JZ; Bi DS; Ma R
Ai Zheng; 2003 Apr; 22(4):376-9. PubMed ID: 12703992
[TBL] [Abstract][Full Text] [Related]
19. Effect of tamoxifen, methoxyprogesterone acetate and combined treatment on cellular proliferation and apoptosis in SKOV3/DDP cells via the regulation of vascular endothelial growth factor.
Wen L; Hong D; Yanyin W; Mingyue Z; Baohua L
Arch Gynecol Obstet; 2013 May; 287(5):997-1004. PubMed ID: 23212665
[TBL] [Abstract][Full Text] [Related]
20. Antitumor action of physiological estradiol on tamoxifen-stimulated breast tumors grown in athymic mice.
Yao K; Lee ES; Bentrem DJ; England G; Schafer JI; O'Regan RM; Jordan VC
Clin Cancer Res; 2000 May; 6(5):2028-36. PubMed ID: 10815929
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]